ESMO

Keytruda Improves Disease-Free Survival in Some With Urothelial Carcinoma

September 20th 2024, 7:00pm

Article

Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived without signs of cancer.

Survival Rate Increased With Yervoy-Opdivo Combo in Kidney Cancer

September 20th 2024, 1:00pm

Article

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with Yervoy plus Opdivo.

Study Confirms Lenvima’s Benefits in Thyroid Cancer

September 19th 2024, 9:00pm

Article

First-time treatment with Lenvima continues to outperform other treatments for thyroid cancer.

Braftovi Regimen Is Promising in Metastatic Colorectal Cancer

September 19th 2024, 1:00pm

Article

In patients with BRAF V600E-mutant metastatic colorectal cancer, a combination of Braftovi, Erbitux and chemotherapy showed promising antitumor activity.

Kisqali Plus Aromatase Inhibitor Shows Benefits in HR+/HER2- Breast Cancer

September 18th 2024, 1:00pm

Article

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.

Adaptive NSCLC Study Fails to Produce Improved Results, Clinical Benefits in Some

September 17th 2024, 3:02pm

Article

Imfinzi with monalizumab and ceralasertib showed promising long-term benefits in advanced NSCLC, but no other combinations significantly improved results.

Presurgical Cetrelimab With TAR-200 Shows Responses in Muscle-Invasive Bladder Cancer

September 16th 2024, 10:00pm

Article

Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of death, research shows.

AI May Predict Cancer Mutations in Lung, Other Cancers

September 16th 2024, 9:00pm

Article

An artificial intelligence model was shown to predict tumor mutation burden in lung cancer and other diseases.

Breastfeeding Is OK in Breast Cancer Subset During Hormone Therapy Break

September 16th 2024, 7:00pm

Article

In patients with HR-positive breast cancer who recently gave birth, breastfeeding is OK during a break from receiving hormone therapy.

Targeted Therapy Outperforms Standard Care in Metastatic Solid Cancers

September 16th 2024, 4:29pm

Article

Patients with metastatic disease whose cancers were tested and treated for specific mutations tended to have better outcomes than those given the standard of care.